## AMENDMENTS TO THE SPECIFICATION

Amendments to the specification are presented below with replacement paragraphs marked up to show changes made relative to the immediate prior version.

Please delete the paragraph at pages 11-12 lines 26-7 and replace with the following amended paragraph:

The expression "variant" refers to sequences of amino acids nucleic acids which differ from the base sequence from which they are derived in that one or more amino acids within the sequence are substituted for other amino acids. Amino acid substitutions may be regarded as "conservative" where an amino acid is replaced with a different amino acid with broadly similar properties. Non-conservative substitutions are where amino acids are replaced with amino acids of a different type. Broadly speaking, fewer non-conservative substitutions will be possible without altering the biological activity of the polypeptide. Suitably variants will be at least 60% homologous, preferably at least 75% homologous, and more preferably at least 90% homologous to the base sequence. Homology in this instance can be judged for example using the algorithm of Lipman-Pearson, with Ktuple:2, gap penalty:4, Gap Length Penalty:12, standard PAM scoring matrix (Lipman, D.J. and Pearson, W.R., "Rapid and Sensitive Protein Similarity Searches", *Science*, 1985, vol. 227, 1435-1441).

Please delete the paragraph at page 15 lines 26-29 and replace with the following amended paragraph:

Figure 3 illustrates the specific serum antibody responses following a single nasal application of  $1\mu g V$  and  $5\mu g F1$  antigens of *Yersinia pestis* in compositions according to the invention  $\div$ ;

Page 6 of 12

Please delete the paragraph at page 15 lines 31-34 and replace with the following

amended paragraph:

Figures 2-4 illustrates 1, 2 and 4 illustrate the immune response to nasally delivered

tetanus toxoid (TT) using compositions according to the invention where BS is

glycodeoxycholic acid, CYC is dimethyl ß cyclodextrin, and VET is Vitamin E TPGS and

PO is polyornithine;

Please delete the paragraph at page 17 lines 11-15 and replace with the following

amended paragraph:

The results are shown in Figure 3 4. This clearly shows that other compound, in

particular, poly-L-ornithine either free or in microspheres, \(\beta\)-cyclodextrins, deoxycholic acid

and Vitamin E TPGS (the latter being present in amounts of 2.5% w/v) produced enhanced

results.

Please delete the paragraph at page 17 lines 24-29 and replace with the following

amended paragraph:

Further tests were carried out using the methodology of Example 1 but replacing the

Yersinia pestis antigens with tetanus toxoid. Mice were dosed on day 1 with 5 LF toxoid and

on day 49 with 2.5 LF of toxoid. The toxoids where in solution in combination with a variety

of adjuvant chemicals in various concentrations. The results are shown in Figures 2-4 1, 2

and 4.

ATLLIB02 188324.2